angiotensin converting enzyme inhibitors

Summary

Summary: A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Top Publications

  1. ncbi The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
  2. ncbi A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
    M Donoghue
    Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Circ Res 87:E1-9. 2000
  3. ncbi Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    S Yusuf
    Canadian Cardiovascular Collaboration Project Office, Hamilton General Hospital, McMaster University, ON
    N Engl J Med 342:145-53. 2000
  4. ncbi A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
    S R Tipnis
    Proteolysis Research Group, School of Biochemistry and Molecular Biology, University of Leeds, Leeds, United Kingdom
    J Biol Chem 275:33238-43. 2000
  5. pmc Renal and retinal effects of enalapril and losartan in type 1 diabetes
    Michael Mauer
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    N Engl J Med 361:40-51. 2009
  6. ncbi Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 348:383-93. 2003
  7. ncbi Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
    Jackson T Wright
    Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 5014, USA
    JAMA 288:2421-31. 2002
  8. ncbi A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly
    Lindon M H Wing
    School of Medicine, Flinders University, Adelaide, Australia
    N Engl J Med 348:583-92. 2003
  9. ncbi The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
    M Komajda
    Eur Heart J 24:464-74. 2003
  10. ncbi Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
    Fiona Turnbull
    Blood Pressure Lowering Treatment Trialists Collaboration, The George Institute for International Health, University of Sydney, PO Box 576, Newtown, Sydney, New South Wales 2042, Australia
    Lancet 362:1527-35. 2003

Detail Information

Publications344 found, 100 shown here

  1. ncbi The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  2. ncbi A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
    M Donoghue
    Millennium Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Circ Res 87:E1-9. 2000
    ..The full text of this article is available at http://www. circresaha.org...
  3. ncbi Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    S Yusuf
    Canadian Cardiovascular Collaboration Project Office, Hamilton General Hospital, McMaster University, ON
    N Engl J Med 342:145-53. 2000
    ..We assessed the role of an angiotensin-converting-enzyme inhibitor, ramipril, in patients who were at high risk for cardiovascular events but who did not have left ventricular dysfunction or heart failure...
  4. ncbi A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
    S R Tipnis
    Proteolysis Research Group, School of Biochemistry and Molecular Biology, University of Leeds, Leeds, United Kingdom
    J Biol Chem 275:33238-43. 2000
    ..4 kilobase pairs and is most highly expressed in testis, kidney, and heart. This is the first report of a mammalian homolog of ACE and has implications for our understanding of cardiovascular and renal function...
  5. pmc Renal and retinal effects of enalapril and losartan in type 1 diabetes
    Michael Mauer
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    N Engl J Med 361:40-51. 2009
    ..Nephropathy and retinopathy remain important complications of type 1 diabetes. It is unclear whether their progression is slowed by early administration of drugs that block the renin-angiotensin system...
  6. ncbi Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 348:383-93. 2003
    ....
  7. ncbi Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
    Jackson T Wright
    Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 5014, USA
    JAMA 288:2421-31. 2002
    ..Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD...
  8. ncbi A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly
    Lindon M H Wing
    School of Medicine, Flinders University, Adelaide, Australia
    N Engl J Med 348:583-92. 2003
    ..We compared the outcomes in older subjects with hypertension who were treated with angiotensin-converting-enzyme (ACE) inhibitors with the outcomes in those treated with diuretic agents...
  9. ncbi The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
    M Komajda
    Eur Heart J 24:464-74. 2003
    ..Accordingly, the Euro Heart Failure Survey was conducted to ascertain how patients hospitalized for heart failure are managed in Europe and if national variations occur in the treatment of this condition...
  10. ncbi Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
    Fiona Turnbull
    Blood Pressure Lowering Treatment Trialists Collaboration, The George Institute for International Health, University of Sydney, PO Box 576, Newtown, Sydney, New South Wales 2042, Australia
    Lancet 362:1527-35. 2003
    ....
  11. ncbi Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Ann Intern Med 136:604-15. 2002
    ..A multimodal approach that centers on reducing or removing all risk factors associated with the progression of renal disease may decrease the time to remission of the disease for most patients with proteinuric nephropathies...
  12. ncbi The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study
    Mark J Sarnak
    Division of Nephrology, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Ann Intern Med 142:342-51. 2005
    ..Hypertension is a risk factor for progression of chronic kidney disease. The optimal blood pressure to slow progression is unknown...
  13. ncbi The renin-angiotensin system and malignancy
    Eleanor I Ager
    Department of Surgery, Austin Health, University of Melbourne, Heidelberg, Victoria 3084, Australia
    Carcinogenesis 29:1675-84. 2008
    ..Manipulation of the RAS may, therefore, provide a safe and inexpensive anticancer strategy...
  14. pmc Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs
    V Adhiyaman
    Department of Geriatric Medicine, Wrexham Maelor Hospital, Wrexham LL13 7TD, Wales, UK
    J R Soc Med 94:512-4. 2001
    Both angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs can lead to functional renal insufficiency...
  15. ncbi Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
    ..Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril...
  16. ncbi Angiotensin-converting enzyme inhibitors
    N J Brown
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Circulation 97:1411-20. 1998
    ....
  17. ncbi Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    Kenneth Jamerson
    Division of Cardiovascular Medicine, University of Michigan Health System, 24 Frank Lloyd Wright Dr, Lobby M, Ann Arbor, MI 48106, USA
    N Engl J Med 359:2417-28. 2008
    ....
  18. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  19. ncbi Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data
    T H Jafar
    Department of Medicine, The Aga Khan University, Stadium Road, PO Box 3500, Karachi, Pakistan
    Ann Intern Med 135:73-87. 2001
    ..Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria...
  20. ncbi Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production
    Vivek P Singh
    Cardiovascular Research Institute, Texas A and M HSC, Temple, TX 76504, USA
    Am J Physiol Heart Circ Physiol 294:H1675-84. 2008
    ....
  21. ncbi The perindopril in elderly people with chronic heart failure (PEP-CHF) study
    John G F Cleland
    Department of Cardiology, University of Hull, Castle Hill Hospital, Castle Road, Cottingham, Kingston upon Hull HU16 5JQ, UK
    Eur Heart J 27:2338-45. 2006
    ..Few substantial randomized controlled trials have been conducted in this population, none has focussed on patients with evidence of diastolic dysfunction and none has shown clear benefit on symptoms, morbidity, or mortality...
  22. ncbi Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients
    K Okaishi
    Department of Geriatric Medicine, Osaka University Medical School, Suita, Japan
    Am J Hypertens 12:778-83. 1999
    ..24; 95% CI, 0.07-0.88). We conclude that ACE inhibitor use is an independent factor reducing risk of pneumonia among elderly inpatients...
  23. pmc Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial
    Deepa Sumukadas
    Section of Ageing and Health, University of Dundee, Dundee, UK
    CMAJ 177:867-74. 2007
    ..We sought to examine the effect of the angiotensin-converting-enzyme (ACE) inhibitor perindopril on physical function in elderly people with functional impairment who had no heart failure or left ventricular systolic dysfunction...
  24. ncbi Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering
    Yuko Izuhara
    Institute of Medical Sciences and Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan
    J Am Soc Nephrol 16:3631-41. 2005
    ..These benefits of ARB may contribute to the renoprotection observed beyond BP lowering...
  25. ncbi Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure
    L Gullestad
    Section of Clinical Immunology and Infectious Diseases and Research Institute for Internal Medicine, Medical Department A, Rikshospitalet University Hosptial, Oslo, Norway
    J Am Coll Cardiol 34:2061-7. 1999
    ..We examined the effect of long-term treatment with two doses of the angiotensin converting enzyme (ACE) inhibitor enalapril on various immunological variables in patients with chronic congestive heart failure (CHF)...
  26. ncbi Drugs targeting the renin-angiotensin-aldosterone system
    Mohammad Amin Zaman
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Nat Rev Drug Discov 1:621-36. 2002
    ....
  27. ncbi A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
    Arnfried U Klingbeil
    Department of Medicine IV, University of Erlangen Nurnberg, Nuremberg, Germany
    Am J Med 115:41-6. 2003
    ..Antihypertensive medications have different effects on left ventricular mass. We conducted a meta-analysis of double-blind trials that measured the effects of antihypertensive therapy on left ventricular mass...
  28. ncbi Different effect of antihypertensive drugs on conduit artery endothelial function
    Lorenzo Ghiadoni
    Department of Internal Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy
    Hypertension 41:1281-6. 2003
    ..In patients with essential hypertension, ACE inhibitors appear to be the only compounds able to improve conduit artery endothelium-dependent vasodilation...
  29. ncbi Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure
    F N Witherow
    Department of Cardiovascular Research, University of Edinburgh, Royal Infirmary of Edinburgh, Scotland, UK
    Circulation 104:2177-81. 2001
    ....
  30. pmc The barriers to effective management of heart failure in general practice
    J A Hickling
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, Archway Resource Centre, Holborn Union Building, Highgate Hill, London N19 3UA
    Br J Gen Pract 51:615-8. 2001
    ..We recommend further research to establish whether multifaceted intervention programmes based on our findings can improve the management of heart failure in primary care...
  31. ncbi Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor
    Rebecca A Lew
    Department of Biochemistry and Molecular Biology, PO Box 13D, Monash University, Clayton, Victoria 3800, Australia
    Exp Physiol 93:685-93. 2008
    ..e.m., 4.44 +/- 0.56 pmol min-1 ml-1). Future studies of patients with cardiovascular, renal and liver disease will determine whether plasma ACE2 is elevated in parallel with increased tissue levels observed in these conditions...
  32. ncbi The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition
    Steven A Atlas
    James J Peters VA Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468, USA
    J Manag Care Pharm 13:9-20. 2007
    ..Dysregulation of the RAAS plays an important role in the pathogenesis of cardiovascular and renal disorders...
  33. ncbi Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
    Carlos M Ferrario
    Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Circulation 111:2605-10. 2005
    ..As the only known human homolog of ACE, the demonstration that ACE2 is insensitive to blockade by ACE inhibitors prompted us to define the effect of ACE inhibition on the ACE2 gene...
  34. ncbi Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension
    David B Matchar
    Duke Center for Clinical Health Policy Research, Duke Clinical Research Institute, Duke University, and Durham U S Department of Veterans Affairs Medical Center, Durham, North Carolina 27705, USA
    Ann Intern Med 148:16-29. 2008
    ..The relative effectiveness of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for lowering blood pressure is unknown...
  35. ncbi ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice
    M J Soler
    Division of Nephrology and Hypertension, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Kidney Int 72:614-23. 2007
    ..Our study shows that chronic pharmacologic ACE2 inhibition worsens glomerular injury in streptozotocin-induced diabetic mice in association with increased ACE expression...
  36. ncbi Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
    K M Fox
    Cardiology Department, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Lancet 362:782-8. 2003
    ..We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure...
  37. pmc Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis
    Vivek P Singh
    Division of Molecular Cardiology, Department of Medicine, Texas A and M Health Science Center, College of Medicine, Scott and White, Central Texas Veterans Health Care System, Temple, TX, USA
    Diabetes 57:3297-306. 2008
    ..In the present study, we determined whether hyperglycemia activates the cardiac intracellular renin-Ang system (RAS) in vivo and whether ARBs, ACE, or renin inhibitors block synthesis and effects of intracellular Ang II (iAng II)...
  38. ncbi The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes
    Effie L Gillespie
    School of Pharmacy, University of Connecticut, Storrs, USA
    Diabetes Care 28:2261-6. 2005
    ..Patients who utilize either an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes...
  39. doi Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
    S Yusuf
    Lancet 372:1174-83. 2008
    ..We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage...
  40. ncbi Time to abandon microalbuminuria?
    P Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Kidney Int 70:1214-22. 2006
    ..Future studies are needed to identify levels of albuminuria below which therapy is no longer beneficial...
  41. ncbi Effect of a multifactorial intervention on mortality in type 2 diabetes
    Peter Gaede
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 358:580-91. 2008
    ..We evaluated whether this approach would have an effect on the rates of death from any cause and from cardiovascular causes...
  42. ncbi Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial
    J F Mann
    Department of Nephrology and Hypertension, Schwabing General Hospital, LMU, Kolner Platz 1, D-80804 Munchen, Germany
    Ann Intern Med 134:629-36. 2001
    ..Ramipril reduced cardiovascular risk without increasing adverse effects...
  43. ncbi Characteristics and outcomes of patients with heart failure in general practices and hospitals
    Hiroyuki Tsutsui
    Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
    Circ J 71:449-54. 2007
    ..However, very little information is available on this issue in general practice in Japan...
  44. ncbi Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
    Johannes F E Mann
    Schwabing General Hospital, and KfH Kidney Centre, Ludwig Maximilians University Munchen, Germany
    Lancet 372:547-53. 2008
    ..We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage...
  45. ncbi No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database
    Gianluigi Ardissino
    Unit of Pediatric Nephrology, Dialysis and Transplantation, Department of Pediatrics, Via Commenda 9, I 20122 Milano, Italy
    Nephrol Dial Transplant 22:2525-30. 2007
    ..The aim of this study was to investigate whether patients with hypodysplastic CKD (the most common cause of ESRF in children) treated with ACEi show a significantly slower decline in creatinine clearance (Ccr)...
  46. ncbi IgA nephropathy
    James V Donadio
    Division of Nephrology, Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    N Engl J Med 347:738-48. 2002
  47. ncbi Fixed-dose combination lercanidipine/enalapril
    Philip I Hair
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:95-106; discussion 107-8. 2007
    ..Cough was reported in <or=5.2% and peripheral oedema in <or=1.5% of lercanidipine/enalapril recipients...
  48. ncbi The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer
    Volker Fendrich
    Department of Surgery, Philipps University Marburg, Baldingerstrasse, Marburg, Germany
    Gut 59:630-7. 2010
    ..In this study, we used a genetically engineered mouse model of pancreatic cancer to evaluate the chemopreventive potential of these drugs...
  49. ncbi A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    Carl J Pepine
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    JAMA 290:2805-16. 2003
    ..Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials...
  50. ncbi Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventric
    D L Dries
    Clinical Trials Scientific Research Group, The National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    J Am Coll Cardiol 32:695-703. 1998
    ....
  51. ncbi Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    J Hepatol 51:315-21. 2009
    ....
  52. ncbi Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms
    Michael J Sweeting
    MRC Biostatistics Unit, Institute of Public Health, Cambridge, United Kingdom
    J Vasc Surg 52:1-4. 2010
    ..To evaluate whether either angiotensin converting enzyme (ACE) inhibitors or other classes of antihypertensive drug attenuate or increase growth rates of small infrarenal abdominal aortic aneurysms...
  53. ncbi Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3411-9. 2005
    ....
  54. ncbi Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure
    Frederick A Masoudi
    Division of Cardiology, Denver Health Medical Center, Denver, Colo 80204, USA
    Am Heart J 146:250-7. 2003
    ..Our objective was to determine the proportion of older persons meeting enrollment criteria of randomized controlled trials of agents that prolong life in heart failure...
  55. ncbi Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)
    Michel Komajda
    Institut de Cardiologie, Centre Hospitalier GH Pitié Salpêtrière, 47 83 bld de l Hôpital, 75013, Paris Cedex 13, France
    Eur J Heart Fail 6:467-75. 2004
    ..Management guidelines for heart failure recommend ACE-I and beta-blockers. The perception of difficult up-titration might have added to the slow uptake of beta-blockers despite their mortality and morbidity benefits...
  56. ncbi Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors
    Dimitris Georgiadis
    Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Panepistimiopolis, Zografou, Athens, Greece
    Circ Res 93:148-54. 2003
    ..Based on these findings, it might be suggested that the gene duplication of ACE in vertebrates may represent a means for regulating the cleavage of Ang I differently from that of BK...
  57. ncbi Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
    Anushka Patel
    Cardiovascular Division, The George Institute for International Health, University of Sydney, PO Box M201, Missenden Road, Sydney, NSW 2050, Australia
    Lancet 370:829-40. 2007
    ....
  58. ncbi Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
    Biff F Palmer
    Department of Medicine, Division of Nephrology, University of Texas Southwestern Medical School, Dallas 75390 8856, USA
    N Engl J Med 351:585-92. 2004
  59. ncbi Preventing microalbuminuria in type 2 diabetes
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Bergamo, Italy
    N Engl J Med 351:1941-51. 2004
    ....
  60. ncbi Idiopathic membranous nephropathy: diagnosis and treatment
    Fernando C Fervenza
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 3:905-19. 2008
    ....
  61. ncbi Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease
    G B John Mancini
    Division of Cardiology, Vancouver Hospital, Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 47:2554-60. 2006
    ....
  62. ncbi Administration-time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure
    Ramon C Hermida
    Bioengineering and Chronobiology Laboratories, University of Vigo, Campus Universitario, Vigo Pontevedra 36200, Spain
    Curr Opin Nephrol Hypertens 14:453-9. 2005
    ..Accordingly, there is growing interest in how to tailor the treatment of hypertensive patients according to their circadian blood-pressure pattern...
  63. ncbi Renin-angiotensin system and cardiovascular risk
    Roland E Schmieder
    Department of Nephrology and Hypertension, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Lancet 369:1208-19. 2007
    ..Inhibitors of the system-ie, angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are now first-line treatments for hypertensive target organ ..
  64. ncbi Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risore
    P Bellotti
    Associazione Nazionale Medici Cardiologi Ospedalieri of Liguria, Genoa, Italy
    Eur Heart J 22:596-604. 2001
    ....
  65. ncbi Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  66. pmc Barriers to optimum management of heart failure by general practitioners
    R Horne
    Centre for Health Care Research, School of Pharmacy and Biomedical Sciences, University of Brighton
    Br J Gen Pract 49:353-7. 1999
    ..Published research offers clear pointers to the management of heart failure; however, the evidence for implementation into practice is sub-optimal...
  67. ncbi Renin-angiotensin system revisited
    F Fyhrquist
    Minerva Institute for Medical Research and Department of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland
    J Intern Med 264:224-36. 2008
    ..Great expectations are now generated by the introduction of renin inhibitors. Indeed, RAS regulates much more and diverse physiological functions than previously believed...
  68. ncbi Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis
    D L Jennings
    Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA
    Diabet Med 24:486-93. 2007
    ..However, these studies are small in size. We performed a meta-analysis of studies investigating combination therapy for DN...
  69. ncbi The renin-angiotensin system and diabetic nephropathy
    Susan B Gurley
    Division of Nephrology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, NC 27705, USA
    Semin Nephrol 27:144-52. 2007
    ..We provide a general review of the RAS and its role in diabetic nephropathy...
  70. pmc Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)
    Linda F Fried
    Veterans Affairs Pittsburgh Healthcare System and Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylviania 15240, USA
    Clin J Am Soc Nephrol 4:361-8. 2009
    ..This paper discusses the design and key methodological issues that arose during the planning of the study...
  71. ncbi Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial
    M A Pfeffer
    Brigham and Women s Hospital, Boston, Mass, USA
    Circulation 95:2643-51. 1997
    ..Although ACE inhibitor therapy has been shown to reduce mortality in patients with acute myocardial infarction (MI), the optimal dose and the timing of its initiation have not been determined...
  72. ncbi Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?
    A R Houghton
    Department of Cardiovascular Medicine, University Hospital, Nottingham, UK
    Int J Cardiol 59:7-10. 1997
    Treatment with angiotensin converting enzyme inhibitors confers significant morbidity and mortality benefits in patients with heart failure, yet previous studies have repeatedly shown that these drugs are underutilised in general practice...
  73. pmc Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis
    Sankar D Navaneethan
    Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin J Am Soc Nephrol 4:542-51. 2009
    ..We evaluated the benefits and harms of adding selective and nonselective AA in CKD patients already on RAS...
  74. ncbi The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors
    L Wei
    Institut de la Santé et de la Recherche Médicale Unité 36, Paris, France
    J Biol Chem 267:13398-405. 1992
    ..The different inhibitor binding properties of the two domains observed in the present study provide strong evidence for the presence of structural differences between the two active sites of ACE...
  75. ncbi Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker
    Eoin O'Brien
    Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland
    Hypertension 49:276-84. 2007
    ....
  76. ncbi Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study
    Roberto Ferrari
    Department of Cardiology, University of Ferrara, Italy
    Arch Intern Med 166:659-66. 2006
    ..Angiotensin-converting enzyme inhibitors reduce mortality and remodeling after myocardial infarction in patients with left ventricular dysfunction...
  77. ncbi Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research
    Carlos M Ferrario
    The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston Salem, NC 27157 1032, USA
    J Renin Angiotensin Aldosterone Syst 7:3-14. 2006
    ..It is hoped that the next 100 years of research into the RAS will uncover hitherto unimaginable therapeutic opportunities...
  78. ncbi Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure
    Akihiro Tojo
    Division of Nephrology and Endocrinology, Department of Internal Medicine, University of Tokyo, Tokyo, Japan
    Hypertension 40:834-9. 2002
    ..In conclusion, DSHF rats showed increased oxidative stress in the kidney via NAD(P)H oxidase. Blockade of local angiotensin II with subpressor dose of imidapril inhibited NAD(P)H oxidase and prevented renal damage...
  79. ncbi Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
    Folkert W Asselbergs
    Department of Clinical Pharmacology, University of Groningen, Groningen, The Netherlands
    Circulation 110:2809-16. 2004
    ..We assessed whether therapeutic intervention aimed at lowering urinary albumin excretion would reduce cardiovascular events in microalbuminuric subjects (15 to 300 mg/24 hours)...
  80. ncbi ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients
    Raymond J Gibbons
    J Am Coll Cardiol 41:159-68. 2003
  81. ncbi Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis
    Agostino Molteni
    Department of Pathology and Basic Medicinal Science, University of Missouri at Kansas City, Truman Medical Center, Kansas City, MO 64108, USA
    Curr Pharm Des 13:1307-16. 2007
    ....
  82. ncbi Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease
    Carlos M Ferrario
    Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Am J Cardiol 98:121-8. 2006
    ....
  83. ncbi Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA
    Joshua I Barzilay
    Kaiser Permanente of Georgia, USA
    Arch Intern Med 166:2191-201. 2006
    ....
  84. ncbi Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III
    Ronnie Willenheimer
    Department of Cardiology, University Hospital, Lund University, Malmo, Sweden
    Circulation 112:2426-35. 2005
    ..In patients with chronic heart failure (CHF), a beta-blocker is generally added to a regimen containing an angiotensin-converting-enzyme (ACE) inhibitor. It is unknown whether beta-blockade as initial therapy may be as useful...
  85. ncbi Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats
    Jeanette M Wood
    Novartis Institute for Biomedical Research, Basel, Switzerland
    J Hypertens 23:417-26. 2005
    ..We report the results of animal experiments performed in marmosets and rats in order to characterize aliskiren before its recent investigation in humans...
  86. ncbi Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases
    H Zhang
    Department of Cardiology, Friedrich Alexander University Erlangen Nurnberg, Germany
    Cardiovasc Res 44:215-22. 1999
    ..These events finally lead to rapid progression of AS and MI. In the present study, we investigate whether ANG II can induce O2- release from human vascular endothelial cells (HVECs) and the possible mechanisms involved...
  87. ncbi Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system
    J F Reckelhoff
    Department of Physiology and Biophysics, The Center for Excellence in Cardiovascular Renal Research, University of Mississippi Medical Center, Jackson 39216 4505, USA
    Hypertension 35:480-3. 2000
    ..However, the data further suggest that androgens promote the exacerbation of hypertension in male SHR via a mechanism involving the renin-angiotensin system...
  88. ncbi Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data
    S Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Epidemiol 154:854-64. 2001
    ..7% and 6.2%, respectively) for predicting mortality. Generalizability of results may be limited to an elderly, predominantly White population with equal access to state-funded health care...
  89. ncbi Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications
    Gunter Wolf
    Department of Medicine, Division of Nephrology, Osteology, and Rheumatology, University of Hamburg, Hamburg, Germany
    Kidney Int 67:799-812. 2005
    ..In our opinion patients with proteinuria >1 g/day despite optimal blood pressure control under RAS-blocking monotherapy are a high-risk group which will presumably benefit from combination therapy...
  90. ncbi Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study
    Ihab M Hajjar
    Institute for Aging Research Hebrew SeniorLife, Harvard Medical School, and the Beth Israel Deconess Medical Center, Boston, Massachusetts 02131, USA
    Am J Alzheimers Dis Other Demen 23:77-83. 2008
    We previously reported that angiotensin converting enzyme inhibitors (ACEIs) decrease the rate of cognitive decline in elderly patients with hypertension, but their impact on patients with Alzheimer's disease (AD) is not known...
  91. ncbi Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure
    A P Guerin
    , , , , , Paris, France
    Circulation 103:987-92. 2001
    ....
  92. pmc Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
    C E Mogensen
    Department of Medicine, M, Kommunehospitalet, University Hospital, DK 8000 Aarhus C, Denmark
    BMJ 321:1440-4. 2000
    ..To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes...
  93. ncbi Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?
    Aarif Y Khakoo
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:9112-5. 2008
    ..If proven correct, this hypothesis carries many implications for the medical practices of cardiology, oncology, and neonatology...
  94. ncbi Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists
    Albert Quan
    Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9063, USA
    Early Hum Dev 82:23-8. 2006
    ..The use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers both control hypertension by interruption of the production or ..
  95. ncbi Myocardial infarction increases ACE2 expression in rat and humans
    Louise M Burrell
    Department of Medicine, University of Melbourne, Austin Health, Repatriation Heidelberg Hospital, Heidelberg 3081, Victoria, Australia
    Eur Heart J 26:369-75; discussion 322-4. 2005
    ..We studied the expression of ACE2 after myocardial infarction (MI) in the rat as well as in human failing hearts...
  96. ncbi Barriers to diagnosing and managing heart failure in primary care
    Susan M Phillips
    National Institute of Clinical Studies, Melbourne, Vic
    Med J Aust 181:78-81. 2004
    ..To explore potential barriers to the optimal diagnosis and management of heart failure in primary care...
  97. ncbi Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time
    Samuel Ryu
    Department of Radiation Oncology and Neurosurgery, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202, USA
    J Neurooncol 82:119-24. 2007
    ..This study was to determine the optimum dose and administration time of ramipril for mitigating radiation-induced optic neuropathy...
  98. pmc Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure
    M H Chin
    Section of General Internal Medicine, University of Chicago (Ill) Medical Center 60637, USA
    J Gen Intern Med 12:523-30. 1997
    ..Educational efforts should focus on these indications and emphasise the dosages demonstrated to lower mortality and morbidity in the trials...
  99. ncbi Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...
  100. ncbi Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
    ..We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor...

Research Grants75

  1. Pharmacogenetics and Cardiovascular Events
    Bruce Psaty; Fiscal Year: 2006
    ..The primary defense is replication: we would therefore welcome collaboration from others in the Pharmacogenetics Network in validation efforts. ..
  2. Discovery metabolite profiling of the prolyl peptidases
    Alan Saghatelian; Fiscal Year: 2009
    ..Furthermore, the application of DMP to peptidases will demonstrate the generality of this approach for the future characterization of medically relevant enzymes and signaling pathways. ..
  3. The Kallikrein/Kinin-Mast Cell Interaction in Volume Overload
    CHIH CHANG KEVIN WEI; Fiscal Year: 2013
    ....
  4. Gene Therapy with Cardiotropic Vectors for the Treatment of Heart Failure
    Roger J Hajjar; Fiscal Year: 2013
    ..The impact of angiotensin converting enzyme inhibitors (ACEI) and b-blockers has translated into more sustained benefit, but many patients become ..
  5. Purkinje Origin of Ischemic Ventricular Tachycardia and Fibrillation
    James B Martins; Fiscal Year: 2013
    ..herein could be pursued immediately in clinical trials since readily available drugs, statins or angiotensin converting enzyme inhibitors, may be combined for their oxidant and calcium/calmodulin kinase blocking effects to prevent ..
  6. An Aldosterone-Endothelin Feedback Mechanism on Sodium Homeostasis
    Charles S Wingo; Fiscal Year: 2012
    ..Importantly, these studies will lend understanding into a novel signaling pathway that may explain the role of aldosterone in the progression of cardiovascular and renal disease. ..
  7. New drug Vida-5 for treating chronic kidney disease progression
    Jinshyun Ruth Wu-Wong; Fiscal Year: 2011
    ....
  8. ANGIOTENSIN II SIGNAL TRANSDUCTION
    Bradford C Berk; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: The healing of tissues after surgery or trauma is critical for long-term survival. The proposed work will study novel mechanisms by which blood vessels grow in response to tissue injury. ..
  9. Novel drug VS-105 for treatment of diabetic nephropathy
    Jinshyun Ruth Wu-Wong; Fiscal Year: 2012
    ....
  10. Endogenous Aldosterone and Glucose Homeostasis
    JAMES MATTHEW LUTHER; Fiscal Year: 2013
    ..In this proposal we will test the hypothesis that the endogenous RAAS impairs peripheral insulin sensitivity, hepatic insulin sensitivity, and insulin secretion in humans via aldosterone. ..
  11. Renin-angiotensin and fibrinolysis interaction in humans
    NANCY JOAN BROWN; Fiscal Year: 2013
    ....
  12. Phospholemman and Cardiac Contracility
    Joseph Y Cheung; Fiscal Year: 2013
    ..In addition, the exact molecular site in sodium-calcium exchanger interacting with phospholemman will be mapped out by mutagenesis. ..
  13. STATINS AND ACE INHIBITORS IN ADULTS WITH DIABETES AND COMORBID CONDITIONS
    David E Grembowski; Fiscal Year: 2010
    ....
  14. Comparative safety &effectiveness of antihypertensive medications in pregnancy
    BRIAN THOMAS BATEMAN; Fiscal Year: 2013
    ..outcome?" We will also examine the safety of first trimester exposure to thiazide diuretics and angiotensin converting enzyme inhibitors, which are the most common types of antihypertensives used in women of reproductive age outside ..
  15. Development of the orally delivered, non-absorbable ACE inhibitor enalaprilat for
    ELKE LIPKA; Fiscal Year: 2010
    ..The goal is the development of a medicine with proven safety that can be easily taken by mouth both during a flare-up of the disease as well as a maintenance treatment. ..
  16. Residual Kidney Function in ESRD: Measurements, Serum Markers and Outcomes
    Tariq Shafi; Fiscal Year: 2013
    ..conduct a pilot randomized clinical trial to determine if RKF can be preserved by treatment with angiotensin converting enzyme inhibitors. The candidate for this mentored Career Development Award is an Instructor of Medicine in the ..
  17. Inhibition of Carboxylesterase Metabolism by Ethanol
    Robert B Parker; Fiscal Year: 2011
    ..Understanding this interaction is a necessary component for the safe and effective use of drugs metabolized by carboxylesterases. ! ..
  18. Pharmacogenetics of ACE inhibitor-associated angioedema
    NANCY JOAN BROWN; Fiscal Year: 2013
    ....
  19. Renin angiotensin system and connexin43
    Samuel C Dudley; Fiscal Year: 2013
    ..Specifically, this application will give a more complete picture of the pro-arrhythmic effects of AngII on heart, which could lead to new diagnostic and therapeutic interventions. ..
  20. Longitudinal Impact of Antihypertensive Polypharmacy on Geriatric Syndromes
    Joseph T Hanlon; Fiscal Year: 2012
    ..eight classes: 1) beta blockers;2) peripheral alpha blockers;3) calcium channel blockers;4) angiotensin converting enzyme inhibitors;5) angiotensin receptor blockers;6) direct vasodilators;7) diuretics and 8) central alpha ..
  21. Prevention of Diabetic Neuropathy with ACE Inhibitors
    MARK ANTHONY YOREK; Fiscal Year: 2012
    ..If successful, these studies could provide a rationale for designing clinical studies to further test the efficacy of angiotensin converting enzyme and/or vasopeptidase inhibitor treatment in human diabetic neuropathy. ..
  22. Novel Aspects of the Cardiac Renin-Angiotensin System
    KENNETH MELVIN BAKER; Fiscal Year: 2012
    ..renin-angiotensin system, may provide substantial benefit for the prevention/treatment of diabetic cardiomyopathy, compared to standard therapy with angiotensin receptor blockers and angiotensin converting enzyme inhibitors.
  23. Low Thyroid function and myocardial infarction
    Anthony Martin Gerdes; Fiscal Year: 2013
    ..from myocardial infarction (MI) has improved with the use of 2-adrenergic blockers (BB) and angiotensin converting enzyme inhibitors (ACEi)...
  24. A Family Partnership Intervention for Heart Failure
    Sandra Dunbar; Fiscal Year: 2009
    ..measures are dietary sodium (24-hour urinary sodium), medication adherence to HF drugs including angiotensin converting enzyme inhibitors and diuretics (Medication Event Monitoring System), heart failure severity (brain natriuretic ..
  25. Development of lisinopril for post-exposure mitigation of late effects from a rad
    MEETHA M MEDHORA; Fiscal Year: 2013
    ..We have organized an efficient as well as responsive research plan, team of experts and well trained personnel to meet our goals. ..
  26. MOLECULAR ASPECTS OF ALPORT RENAL DISEASE PROGRESSION
    DOMINIC E COSGROVE; Fiscal Year: 2013
    ..Currently the 1 in 20,000 people with the disease are treated with ACE inhibitors, dialysis, and transplant. This work utilizes animal models to explore new therapeutic targets aimed at arresting the disease in its early stages. ..
  27. Associations among RAAS Inhibitors, Residual Kidney Function, and CV Events in PD
    Jenny I Shen; Fiscal Year: 2013
    ..Further, the size of the database will allow us to study relevant patient subgroups. ..
  28. 2010 Angiotensin Gordon Research Conference
    Kathy K Griendling; Fiscal Year: 2010
    ..Research into the actions of angiotensin continues to provide new avenues for treating patients with cardiovascular disease, thereby prolonging life and its quality. ..
  29. Improving Methods for Comparative Effectiveness Research in Cardiovascular Care
    SOKO SETOGUCHI-IWATA; Fiscal Year: 2012
    ..This award would play an important role in the applicant's development as an outstanding researcher who can provide leadership in CE research for CVD, especially in large database methods. ..
  30. Vitamin D Deficiency Augments Renin-Angiotensin System Activity in Obesity
    Anand Vaidya; Fiscal Year: 2011
    ..This project aims to examine whether Vitamin D supplementation in obesity reduces RAS activity in humans. ..
  31. Safety and Effectiveness Evaluations for Kidney Disease in Complex Patients
    DONALD READ MILLER; Fiscal Year: 2010
    ..will be made within the following classes or groups of medications recommended for treating CKD: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and HMGcoA reductase inhibitors (statins)...
  32. Effect of Statin Therapy on Disease Progression in Children with ADPKD
    Robert W Schrier; Fiscal Year: 2012
    ..and young adults with autosomal dominant polycystic kidney disease (ADPKD) who are receiving angiotensin converting enzyme inhibitors. The primary endpoint of the study will be achieved in subjects with 20% or greater change over ..
  33. University of Iowa Older Adults CERT
    Elizabeth A Chrischilles; Fiscal Year: 2010
    ..3. Educate providers, patients, and policy makers about therapeutic decision-making in the elderly. ..
  34. Biventricular Pacing in Heart Failure
    SAMIR FAWZI SABA; Fiscal Year: 2010
    ..New York Heart Association Class III-IV) despite optimal pharmacologic therapy including angiotensin converting enzyme inhibitors, b-blockers, and potassium-sparing diuretics can extract benefits from BIV pacing in the form of ..
  35. Gender Disparities and Vascular Function in Chronic Kidney Disease Outcomes
    ANA CATHERINE RICARDO; Fiscal Year: 2013
    ..This Career Development Award will provide the foundation for Dr. Ricardo to pursue an independent research career dedicated to reducing health disparities in CKD. ..
  36. Longitudinal Impact of Antihypertensive Polypharmacy on Geriatric Syndromes
    Joseph T Hanlon; Fiscal Year: 2010
    ..of seven medication classes: 1) beta blockers;2) alpha blockers;3) calcium channel blockers;4) angiotensin converting enzyme inhibitors;5) angiotensin receptor blockers;6) direct vasodilators;and 7) diuretics)...
  37. Strategies for ACE2 Amplification to Treat Diabetic Kidney Disease
    Daniel Batlle; Fiscal Year: 2012
    ....
  38. Effects of ACE Inhibitor (ACEI) use on bone turnover in humans: a clinical trial
    NAHID JAMAL RIANON; Fiscal Year: 2013
    ..Antihypertensive medications affecting RAS, specifically angiotensin converting enzyme inhibitors (ACEI), decreased bone turnover in animals, and improved BMD in preliminary human studies...
  39. Role and Relevance of Pept1 in Drug Absorption, Disposition, and Dynamics
    David E Smith; Fiscal Year: 2013
    ..Finally, the proposed studies may offer rare insight into the variability of peptide/mimetic kinetics and response in those human subjects with genetic polymorphisms. ..
  40. ACE and ACE2 in Glomerular Angiotensin Peptides Metabolism
    JAN ANDRZEJ WYSOCKI; Fiscal Year: 2010
    ..This proposal will provide a better understanding of ACE and ACE2 in diabetic kidney disease and has the promise to offer novel insights into ways to protect the kidney from diabetes related damage. ..
  41. Interactive Spaced Education to Optimize Diabetes Care
    B Price Kerfoot; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Randomized trials have clearly shown that angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) substantially reduce morbidity and mortality in patients with ..
  42. Limited Competition: Clinical Centers for the HALT-Polycystic Kidney Disease Tria
    Arlene B Chapman; Fiscal Year: 2013
    ..These include Angiotensin Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blocking Agents (ARB)...
  43. Longitudinal C-Reactive Protein Levels and Outcomes in Hemodialysis Patients
    JONATHAN WILLIAM BAZELEY; Fiscal Year: 2010
    ....
  44. Microvascular disease, statins, ACE-inhibitors and post-operative SBO
    FRANK IRVING SCOTT; Fiscal Year: 2013
    ..This research will serve as the foundation for future prospective evaluation of the effect of risk factor modification and medication use to prevent adhesion-related SBO. ..
  45. Renin Angioensin Aldosterone System in Drub Abuse and HIV-associated Nephropathy
    Pravin C Singhal; Fiscal Year: 2013
    ..Based on our preliminary data, we hypothesize that modulation of RAAS by its selective inhibitors will not only prevent or attenuate HIV-1- induced renal injury but also delay or slow down the progression of HIVAN. ..
  46. Prospective meta-analyses of drug-gene interactions: CHARGE GWAS consortium
    Bruce M Psaty; Fiscal Year: 2013
    ..Public-health relevance: This broad-based discovery effort is likely to illuminate novel biologic mechanisms, affect how some drugs are prescribed, and identify novel targets for new therapies. ..
  47. Management and Outcomes of Heart Failure with Preserved Systolic Function
    Alan S Go; Fiscal Year: 2010
    ....
  48. Research Centers in Minority Institutions Clinical Rese*
    Eve Higginbotham; Fiscal Year: 2009
    ..IV. Define the efficacy of chronic treatment with angiotensin converting enzyme inhibitors as a means to improve endothelial function in African-American hypertensives with baseline ..
  49. Development of ACE Inhibitor as Countermeasure for Radiation-Induced Lung Injury
    MEETHA M MEDHORA; Fiscal Year: 2010
    ..Specifically we propose to accelerate development of FDA-approved Angiotensin Converting Enzyme inhibitors (ACEi), captopril, enalapril or fosinopril for safe and effective mitigation and treatment...
  50. Pharmaconeuropathology of Brain Aging and Dementia
    Joshua A Sonnen; Fiscal Year: 2013
    ..abstract_text> ..
  51. The Alport Syndrome Symposium for Physicians, Researchers and Families
    Clifford E Kashtan; Fiscal Year: 2010
    ..beneficial interventions, including medications used routinely by nephrologists such as angiotensin converting enzyme inhibitors. Any intervention trial in Alport syndrome will require the active engagement and participation ..
  52. Improving management of cardiovascular medications during hospitalization
    Andrew D Auerbach; Fiscal Year: 2013
    ..Moreover, the mentorship program will develop researchers with a skillset that will be critical during an era which will place even greater priority on translation of evidence into practice. (End of Abstract) ..
  53. Should the elderly have lower dose of ACE inhibitors for prevention after AMI?
    Gang Fang; Fiscal Year: 2013
    ....
  54. Pharmacepidemiology in the elderly: medications pneumonia risk and confounding
    Sascha Dublin; Fiscal Year: 2011
    ..It also will provide information on potentially reversible causes of pneumonia, a common and often devastating illness, and contribute to improved methods in studies of medication effects in the elderly. ..
  55. Impact of Comorbidity Dyads on Heart Failure Treatment in Older Persons
    Jerry H Gurwitz; Fiscal Year: 2013
    ..abstract_text> ..
  56. Impact of New Technologies on Chronic Heart Failure Outcomes and Costs in the VHA
    Peter W Groeneveld; Fiscal Year: 2013
    ....
  57. Nocturnal Hypertension and Prevention of Microalbuminuria in Type I Diabetics
    MARK ELLIS MOLITCH; Fiscal Year: 2010
    ..Moreover, these studies will reveal the impact of long-term ACE inhibition on nocturnal hypertension and endothelial dysfunction in normotensive type 1 diabetics. ..
  58. Genome-wide case-only study of antihypertensive drug-gene interactions
    Bruce M Psaty; Fiscal Year: 2010
    ....
  59. Comparative Effectiveness of ACE Inhibitors for African Americans
    GBENGA GODWIN OGEDEGBE; Fiscal Year: 2011
    ....
  60. Pathophysiological role of prorenin in CKD
    Alfred K Cheung; Fiscal Year: 2013
    ..Hence, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) have been used extensively to treat these clinical ..
  61. ACE Inhibition and Cardiac Allograft Vasculopathy
    William F Fearon; Fiscal Year: 2013
    ..b>Angiotensin converting enzyme inhibitors are used in less than one half of transplant recipients...
  62. RAS and Injury
    Kenneth E Bernstein; Fiscal Year: 2013
    ..Given the very large number of people taking ACE inhibitors, and the fact that all ACE inhibitors raise AcSDKP level, it is important to understand the physiologic effects of high AcSDKP. ..
  63. Systems Biology of Anionic Drug and Metabolite Handling
    Sanjay K Nigam; Fiscal Year: 2012
    ..The ultimate goal is to set the stage for a model with predictive power in the clinical contexts of complex metabolic disease phenotypes (eg. hyperuricemia) and pharmacogenomics. ..
  64. Angiotensin II and diabetic retinopathy
    ALFONSO SCICLI; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): Clinical trials suggest that Angiotensin Converting Enzyme inhibitors (ACEi) slow the progression of diabetic retinopathy...
  65. BRADYKININ VASCULAR INFLUENCE AND ACE INHIBITION
    BEN ZIMMERMAN; Fiscal Year: 1993
    ....
  66. ROLE OF GLUCOSE IN hAT1 GENE EXPRESSION
    Thomas Thekkumkara; Fiscal Year: 2009
    ..With this information we are hoping to obtain a better understanding of the receptor action, and also a direction in the management and treatment of kidney diseases in diabetes. ..
  67. VASCULAR INTERACTION WITH AGE IN MYOCARDIAL INFARCTION
    Steven Schulman; Fiscal Year: 2004
    ..We anticipate that the study findings will suggest the use of new evaluation and therapeutic strategies, which will significantly decrease the age associated mortality and morbidity in post-infarction patients. ..
  68. Labeled inhibitors for angiotensin converting enzyme
    John Babich; Fiscal Year: 2004
    ..abstract_text> ..
  69. Bradykinin Receptor Antagonism During Cardiopulmonary Bypass
    Mias Pretorius; Fiscal Year: 2010
    ..These studies promise to provide important information regarding the effects of drugs that interrupt the RAS and generate new strategies to reduce morbidity in patients undergoing CPB. ..
  70. EFFECTS OF DIFFERENTIAL COST SHARING IN THE ELDERLY
    Stephen Soumerai; Fiscal Year: 1999
    ..and comparison series, will assess the impact of DCS for blood pressure lower drugs, specifically angiotensin converting enzyme inhibitors (ACEI) and calcium channel blockers (CCB), on drug utilization and drug switching in elderly ..
  71. ACE Inhibition and Novel Cardiovascular Risk Factors
    Marco Pahor; Fiscal Year: 2004
    b>Angiotensin converting enzyme inhibitors (ACE inhibitors) may prevent cardiovascular events in high risk persons and improve skeletal muscle function in heart failure patients by means of mechanisms that are independent of blood pressure ..
  72. Clinical Impact of Bradykinin Receptor Polymorphisms
    James Gainer; Fiscal Year: 2005
    ..through a B2 receptor dependent-mechanism, is an integral contributor to the efficacy of angiotensin converting enzyme inhibitors. Animal studies suggest that genetic variation altering the regulation or function of the B2 ..
  73. Hypertension and Collagen: Effect of Ac-SDKP
    Nour Eddine Rhaleb; Fiscal Year: 2010
    ..Consequently, it will identify another component (Ac-SDKP) as part of the multiple mediators participating in the cardioprotective effects of ACEi in hypertension. ..
  74. Effects of the DASH Diet in Albuminuria
    David Jacobs; Fiscal Year: 2003
    ..Thus we will test the hypothesis that the DASH dietary pattern ameliorates albuminuria. Reduction of albuminuria and the underlying defects that it represents is an important medical and public health goal. ..
  75. SOFTWARE EFFECT ON PROMOTING ADHERENCE TO CHF GUIDELINES
    Lawrence Baruch; Fiscal Year: 2005
    ..atrial fibrillation, beta-blockers in patients post myocardial infarction, and beta-blockers and angiotensin converting enzyme inhibitors in patients with systolic left ventricular dysfunction...